Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human miR-133a antisense nucleic acid and application thereof

An antisense and oligonucleotide technology, applied in the field of biomedical materials, can solve the problems of poor curative effect in patients with distant metastasis, low survival rate of middle and advanced patients, and low survival rate, so as to inhibit growth and malignant proliferation effect of ability

Active Publication Date: 2012-12-26
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In the past 30 years, although the comprehensive treatment of tumors has been very common clinically, the comprehensive treatment based on surgery and supplemented by radiotherapy and chemotherapy has not significantly improved the survival rate of cancer patients, and the 5-year overall survival rate is still low, hovering At about 30% to 55%, there is no significant improvement, and the 5-year survival rate of middle and advanced patients is even lower, about 20%.
Moreover, these methods have their own limitations, especially for the middle-advanced and relapsed patients, and the curative effect is even worse for those with distant metastasis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human miR-133a antisense nucleic acid and application thereof
  • Human miR-133a antisense nucleic acid and application thereof
  • Human miR-133a antisense nucleic acid and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1. Detection of inhibitory activity of miR-133a antisense oligonucleotides on human glioma cell line U87 / MG

[0033] First, the miR-133a antisense oligonucleotide was synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd., the sequence is: 5'-CAGCUGGUUGAAGGGGACCAAA-3'. All the sequences used in the examples were synthesized by Shanghai Gemma Pharmaceutical Technology Co., Ltd.

[0034] Cell culture:

[0035] U87 / MG cells (purchased from the Cell Bank of the Type Culture Collection Committee of the Chinese Academy of Sciences), cultured in 10% FBS-DMEM medium (FBS was purchased from Gibco, DMEM was purchased from Hyclone), 37 ° C, 5% CO 2 to cultivate. Collect U87 / MG cells in good growth state, count by centrifugation, and use 2×10 3 Spread each well in a 96-well plate at 37°C, 5% CO 2 Cultivate for 24h.

[0036] Transfection:

[0037] 1) One day before transfection, inoculate cultured cells in a 96-well plate with an appropriate amount of culture...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antisense oligonucleotide which can inhibit the expression of human microRNA-133a and application thereof. The antisense oligonucleotide specificity is combined with the human miR-133a and contains the consecutive nucleotide sequences complementary with the following nucleotide sequence: 5'-UUUGGUCCCCUUCAACCAGCUG-3', especially 5'-CAGCUGGUUGAAGGGGACCAAA-3'. The antisense oligonucleotide can be used as the chimera of ribonucleotides or deoxyribonucleotides or ribonucleotide with deoxyribonucleotide and can modify any nucleotide in the chains. The miR-133a antisense oligonucleotide can effectively inhibit the miR-133a expression in human brain glioma cells, and can inhibit the growth and proliferation of human brain glioma cells, thereby effectively treating brain gliomas and other tumors with high miR-133a expression.

Description

technical field [0001] The invention belongs to the technical field of biomedical materials and the field of medicine. Specifically, the present invention relates to a use of microRNAs (miRNA), in particular to human microRNA-133a (human miR-133a) antisense nucleic acid and its application. The antisense nucleic acid can be complementary to human miR-133a, thereby inhibiting the expression of human miR-133a to play an anti-tumor effect. The invention also relates to a pharmaceutical composition containing the miRNA antisense nucleic acid. Background technique [0002] miRNAs are small non-coding RNAs with a length of 20-25bp, usually transcribed by RNA polymerase II (PolII), and generally the initial product is a large one with a cap structure (7MGpppG) and a polyA tail (AAAAA) pri-miRNA. These pri-miRNAs are processed into pre-miRNA precursor products consisting of 70 nucleotides under the action of RNase III Drosha and its cofactor Pasha. RAN-GTP and exportin 5 transpo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113A61K31/7088A61P35/00A61P35/02A61P25/00
Inventor 丁侃张佩琢李捷东楠沈孝坤
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com